Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization

• Published in: Journal of the American College of Cardiology Vol. 77; no. 3; pp. 259 - 267
• Main Authors: Oyama, Kazuma, Furtado, Remo H.M., Fagundes, Antonio, Zelniker, Thomas A., Tang, Minao, Kuder, Julia, Murphy, Sabina A., Hamer, Andrew, Wang, Huei, Keech, Anthony C., Giugliano, Robert P., Sabatine, Marc S., Bergmark, Brian A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 26.01.2021
• Subjects: Cardiovascular; cholesterol; coronary artery bypass graft surgery; coronary revascularization; evolocumab; Internal Medicine; percutaneous coronary intervention; ASCVD; LDL-C; CI; evolocumab; PCSK9; HR; coronary revascularization; coronary artery bypass graft surgery; percutaneous coronary intervention; PCI; cholesterol; CABG; MI; eGFR; proprotein convertase subtilisin/kexin type 9; Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound; estimated glomerular filtration rate; low-density lipoprotein cholesterol; FOURIER; GLAGOV; myocardial infarction; DM; diabetes mellitus; atherosclerotic cardiovascular disease; Cholesterol; Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk
• ISSN: 0735-1097; 1558-3597; 1558-3597
• DOI: 10.1016/j.jacc.2020.11.011

This study sought to evaluate the ability of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to reduce the risk of complex coronary atherosclerosis requiring revascularization. PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization...